Recent Updates
Recently added Catalysts
ARGX

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Key Takeaway: argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Price reaction · baseline $584.605 (2025-06-02 close) · hit after-hours · clean, no other ARGX news in the window
day 0 close
-1.4%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis

Full Press Release Details

June 3, 2025Amsterdam, the Netherlands– argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46thAnnual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40 AM ET in Miami, FL.
A live webcast of the presentation may be accessed on the Investors section of the argenx website atargenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visitwww.argenx.comand follow us onLinkedIn,Instagram,Facebook, and YouTube.

Investors:

Last updated: Jun 3, 2025